Ok, but still referencing old study/findings. IMS summarizes new analyses:
Key points
-In women under age 60 and recently postmenopausal with no evidence of cardiovascular disease, the initiation of estrogen-alone therapy reduces coronary heart disease (CHD) and all-cause mortality [A]
-Data on daily continuous combined estrogen–progest…
Ok, but still referencing old study/findings. IMS summarizes new analyses:
Key points
-In women under age 60 and recently postmenopausal with no evidence of cardiovascular disease, the initiation of estrogen-alone therapy reduces coronary heart disease (CHD) and all-cause mortality [A]
-Data on daily continuous combined estrogen–progestin are less robust but other combined therapy regimens appear to be protective as shown in Danish and Finnish studies [A]
-Recent meta-analyses and WHI 13-year follow-up data all show a consistent reduction in all-cause mortality for MHT users [A]
-It is not recommended to initiate MHT beyond age 60 years solely for primary prevention of CHD [A]
Ok, but still referencing old study/findings. IMS summarizes new analyses:
Key points
-In women under age 60 and recently postmenopausal with no evidence of cardiovascular disease, the initiation of estrogen-alone therapy reduces coronary heart disease (CHD) and all-cause mortality [A]
-Data on daily continuous combined estrogen–progestin are less robust but other combined therapy regimens appear to be protective as shown in Danish and Finnish studies [A]
-Recent meta-analyses and WHI 13-year follow-up data all show a consistent reduction in all-cause mortality for MHT users [A]
-It is not recommended to initiate MHT beyond age 60 years solely for primary prevention of CHD [A]
https://www.imsociety.org/statements/ims-recommendations/